PriceTargets.com logo

Elanco Animal Health - ELAN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $15.00
  • Forecasted Upside: 15.12%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$13.03 As of 05/13/2025 01:53 PM ET
▲ +0.21 (1.64%)

This chart shows the closing price for ELAN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarAprMay$12.82Closing price on 05/12/25:
Get New Elanco Animal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELAN

Analyst Price Target is $15.00
▲ +15.12% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Elanco Animal Health in the last 3 months. The average price target is $15.00, with a high forecast of $19.00 and a low forecast of $12.00. The average price target represents a 15.12% upside from the last price of $13.03.

This chart shows the closing price for ELAN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
5/248/2411/242/255/255/26$5.70$9.35$13$17$20Closing price on 05/12/25: $12.82High$19.00Average$15.00Low$12.00




Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in Elanco Animal Health. This rating has held steady since September 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/18/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/18/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/16/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
2/12/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/13/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/8/2025Stifel NicolausBoost TargetBuy ➝ Buy$13.00 ➝ $15.00
4/14/2025Stifel NicolausLower TargetBuy ➝ Buy$15.00 ➝ $13.00
3/6/2025Piper SandlerLower TargetNeutral ➝ Neutral$16.00 ➝ $12.00
2/26/2025UBS GroupLower TargetBuy ➝ Buy$18.00 ➝ $17.00
2/26/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $13.00
2/26/2025BarclaysLower TargetOverweight ➝ Overweight$20.00 ➝ $19.00
2/21/2025Stifel NicolausLower TargetBuy ➝ Buy$18.00 ➝ $16.00
1/29/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$15.00 ➝ $14.00
1/7/2025Stifel NicolausLower TargetBuy ➝ Buy$20.00 ➝ $18.00
12/9/2024UBS GroupInitiated CoverageBuy$18.00
12/2/2024Leerink PartnrsUpgradeHold
12/2/2024Leerink PartnersInitiated CoverageMarket Perform$14.00
11/8/2024BarclaysBoost TargetOverweight ➝ Overweight$19.00 ➝ $20.00
10/28/2024BarclaysLower TargetOverweight ➝ Overweight$22.00 ➝ $19.00
9/23/2024BarclaysBoost TargetOverweight ➝ Overweight$21.00 ➝ $22.00
9/19/2024Stifel NicolausReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
9/19/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$17.00 ➝ $15.00
7/1/2024Piper SandlerLower TargetNeutral ➝ Neutral$19.00 ➝ $16.00
6/28/2024BarclaysLower TargetOverweight ➝ Overweight$23.00 ➝ $21.00
5/13/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$18.00 ➝ $19.00
5/9/2024BarclaysBoost TargetOverweight ➝ Overweight$19.00 ➝ $23.00
2/27/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$12.50 ➝ $14.00
2/27/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$16.00 ➝ $17.00
2/27/2024BarclaysBoost TargetOverweight ➝ Overweight$18.00 ➝ $19.00
1/17/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$10.00 ➝ $12.50
1/5/2024Stifel NicolausUpgradeHold ➝ Buy$13.00 ➝ $20.00
12/19/2023Jefferies Financial GroupInitiated CoverageBuy$17.00
12/15/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$16.00
12/7/2023Stifel NicolausBoost TargetHold ➝ Hold$12.00 ➝ $13.00
12/7/2023BNP ParibasInitiated CoverageOutperform$18.00
11/13/2023Piper SandlerBoost TargetNeutral ➝ Neutral$11.00 ➝ $12.00
11/8/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.00
10/30/2023Stifel NicolausLower TargetHold ➝ Hold$13.00 ➝ $12.00
10/5/2023Piper SandlerLower Target$13.00 ➝ $11.00
8/14/2023Piper SandlerBoost TargetNeutral ➝ Neutral$9.00 ➝ $13.00
8/8/2023The Goldman Sachs GroupBoost TargetSell ➝ Sell$8.50 ➝ $9.50
4/20/2023BarclaysUpgradeEqual Weight ➝ Overweight$14.00
3/2/2023Piper SandlerLower Target$15.00 ➝ $12.00
2/22/2023BarclaysLower TargetEqual Weight$18.00 ➝ $14.00
1/30/2023Morgan StanleyLower TargetEqual Weight$20.00 ➝ $19.00
11/15/2022Morgan StanleyLower TargetEqual Weight$21.00 ➝ $20.00
11/14/2022Piper SandlerLower TargetNeutral$21.00 ➝ $15.00
11/9/2022The Goldman Sachs GroupLower TargetSell$19.00 ➝ $12.00
11/8/2022William BlairReiterated RatingMarket Perform
10/17/2022JPMorgan Chase & Co.Lower TargetNeutral$24.00 ➝ $20.00
10/7/2022Morgan StanleyLower TargetEqual Weight$22.00 ➝ $21.00
9/12/2022BarclaysLower TargetEqual Weight$32.00 ➝ $18.00
8/18/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$37.00 ➝ $22.00
8/16/2022Piper SandlerLower TargetNeutral$22.00 ➝ $21.00
8/16/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$28.00 ➝ $24.00
7/21/2022The Goldman Sachs GroupDowngradeBuy ➝ Sell$32.00 ➝ $19.00
7/11/2022Piper SandlerInitiated CoverageNeutral$22.00
6/24/2022Stifel NicolausLower TargetHold$30.00 ➝ $22.00
5/19/2022The Goldman Sachs GroupLower TargetBuy$37.00 ➝ $32.00
5/17/2022Morgan StanleyLower TargetOverweight$37.00
2/28/2022BarclaysBoost TargetEqual Weight$30.00 ➝ $32.00
12/8/2021BarclaysReiterated RatingNeutral ➝ Hold
11/18/2021Morgan StanleyInitiated CoverageOverweight$40.00
10/28/2021Stifel NicolausDowngradeBuy ➝ Hold$37.00 ➝ $34.00
8/5/2021Credit Suisse GroupInitiated CoverageOutperform$38.00
5/17/2021CitigroupReiterated RatingBuy$39.00 ➝ $42.00
5/11/2021G.ResearchUpgradeHold ➝ Buy
5/11/2021GabelliUpgradeHold ➝ Buy
5/11/2021BarclaysUpgradeUnderweight ➝ Equal Weight$25.00 ➝ $29.00
4/20/2021Stifel NicolausInitiated CoverageBuy$37.00
4/14/2021Stifel NicolausInitiated CoverageBuy$37.00
3/29/2021GabelliReiterated RatingBuy ➝ Hold$32.00
3/22/2021GabelliDowngradeBuy ➝ Hold$32.00
3/22/2021Raymond JamesReiterated RatingHold
3/8/2021CitigroupBoost Target$35.00 ➝ $39.00
2/26/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$33.00 ➝ $38.00
12/9/2020ArgusDowngradeBuy ➝ Hold
11/23/2020Morgan StanleyBoost TargetOverweight$31.00 ➝ $41.00
11/9/2020BarclaysDowngradeOverweight ➝ Underweight$35.00 ➝ $25.00
10/26/2020BarclaysBoost TargetOverweight$25.00 ➝ $35.00
10/7/2020Raymond JamesReiterated RatingHold
10/1/2020CitigroupBoost TargetBuy$27.00 ➝ $32.00
9/28/2020Raymond JamesReiterated RatingHold
8/20/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$24.00 ➝ $31.00
8/18/2020ArgusBoost TargetPositive ➝ Buy$26.00 ➝ $30.00
8/12/2020Credit Suisse GroupInitiated CoverageNeutral$27.00
8/4/2020The Goldman Sachs GroupInitiated CoverageBuy$26.50
7/20/2020Bank of AmericaBoost TargetBuy$26.00 ➝ $28.00
5/15/2020CitigroupLower TargetBuy$35.00 ➝ $27.00
5/13/2020BarclaysReiterated RatingBuy$25.00
(Data available from 5/13/2020 forward)

News Sentiment Rating

1.07 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 23 very positive mentions
  • 50 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2024
  • 9 very positive mentions
  • 108 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/14/2024
  • 19 very positive mentions
  • 88 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/14/2024
  • 11 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
1/13/2025
  • 8 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/12/2025
  • 26 very positive mentions
  • 20 positive mentions
  • 11 negative mentions
  • 3 very negative mentions
Mentions as of
3/14/2025
  • 27 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
4/13/2025
  • 49 very positive mentions
  • 18 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
5/13/2025

Current Sentiment

  • 49 very positive mentions
  • 18 positive mentions
  • 6 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Elanco Animal Health logo
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Read More

Today's Range

Now: $13.03
Low: $12.61
High: $13.11

50 Day Range

MA: $9.93
Low: $8.14
High: $12.82

52 Week Range

Now: $13.03
Low: $8.02
High: $18.80

Volume

3,094,109 shs

Average Volume

4,990,567 shs

Market Capitalization

$6.47 billion

P/E Ratio

32.58

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Elanco Animal Health?

The following sell-side analysts have issued research reports on Elanco Animal Health in the last twelve months: Barclays PLC, Leerink Partners, Leerink Partnrs, Morgan Stanley, Piper Sandler, Stifel Nicolaus, and UBS Group AG.
View the latest analyst ratings for ELAN.

What is the current price target for Elanco Animal Health?

0 Wall Street analysts have set twelve-month price targets for Elanco Animal Health in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 15.1%. Barclays PLC has the highest price target set, predicting ELAN will reach $19.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $12.00 for Elanco Animal Health in the next year.
View the latest price targets for ELAN.

What is the current consensus analyst rating for Elanco Animal Health?

Elanco Animal Health currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ELAN, but not buy more shares or sell existing shares.
View the latest ratings for ELAN.

What other companies compete with Elanco Animal Health?

Other companies that are similar to Elanco Animal Health include BioNTech, Beigene, Teva Pharmaceutical Industries, Summit Therapeutics and Intra-Cellular Therapies. Learn More about companies similar to Elanco Animal Health.

How do I contact Elanco Animal Health's investor relations team?

Elanco Animal Health's physical mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company's listed phone number is (877) 352-6261 and its investor relations email address is kanaga_tiffany@elanco.com. The official website for Elanco Animal Health is www.elanco.com. Learn More about contacing Elanco Animal Health investor relations.